ystems to improve the infrastructure of quality
assurance operations in support of future growth, for ensuring the
company's products meet corporate and government standards and that quality
assurance activities comply with applicable regulations, and for providing
enhanced expertise and guidance in interpreting government regulations and
guidelines. He most recently held positions at GTC Biotherapeutics
(formerly known as Genzyme Transgenics Corporation), where he served as
vice president of corporate quality, and Stryker Corporation, where he was
director of quality assurance. Mr. Maines holds a bachelor of science
degree in biology/microbiology from Gannon University.
Management Promotions
As vice president, human resources (HR), Mr. Max Donley is responsible
for providing business-integrated leadership and delivering professional
tools, programs and services to optimize MedImmune's human capital
investments through the HR function across all sites to drive business
results. Prior to joining MedImmune in 2000 as a senior manager, he led
field HR and development at Bed Bath & Beyond. Mr. Donley, a certified
senior professional in human resources through the Society for Human
Resource Management, holds a master and a bachelor degree in business
administration from George Mason University and the University of Michigan,
respectively.
Mr. Jonathan Klein-Evans now serves as vice president, intellectual
property, overseeing all intellectual property issues for the company.
Throughout his nearly 15 years in the field, Mr. Klein-Evans has worked on
all aspects of patent law, including prosecution, litigation, opinions,
interferences, oppositions and licensing. He joined MedImmune in 2002 as
director, intellectual property. Previously, Mr. Klein-Evans was an
in-house patent attorney at Human Genome Sciences, Inc. (HGS). Prior to his
tenure at HGS, Mr. Klein-Evans worked for the law firm of Pennie & Edmonds,
LLP, first as a law clerk, then a patent agent,
'/>"/>
SOURCE MedImmune, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production2.
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters3.
MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County4.
MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition5.
AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results